SG11201903209TA - Structures and mechanism for the design of highly potent glucocorticoids - Google Patents
Structures and mechanism for the design of highly potent glucocorticoidsInfo
- Publication number
- SG11201903209TA SG11201903209TA SG11201903209TA SG11201903209TA SG11201903209TA SG 11201903209T A SG11201903209T A SG 11201903209TA SG 11201903209T A SG11201903209T A SG 11201903209TA SG 11201903209T A SG11201903209T A SG 11201903209TA SG 11201903209T A SG11201903209T A SG 11201903209TA
- Authority
- SG
- Singapore
- Prior art keywords
- ova
- international
- compounds
- pct
- grand rapids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0042—Nitrogen only
- C07J71/0047—Nitrogen only at position 2(3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662408314P | 2016-10-14 | 2016-10-14 | |
| PCT/US2017/056447 WO2018071736A1 (en) | 2016-10-14 | 2017-10-13 | Structures and mechanism for the design of highly potent glucocorticoids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903209TA true SG11201903209TA (en) | 2019-05-30 |
Family
ID=61906432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903209TA SG11201903209TA (en) | 2016-10-14 | 2017-10-13 | Structures and mechanism for the design of highly potent glucocorticoids |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10954265B2 (ru) |
| EP (1) | EP3525870B1 (ru) |
| JP (2) | JP7146750B2 (ru) |
| KR (1) | KR102497070B1 (ru) |
| CN (1) | CN110382033B (ru) |
| ES (1) | ES2945983T3 (ru) |
| MA (1) | MA46539A (ru) |
| PH (1) | PH12019500801A1 (ru) |
| RU (1) | RU2019111101A (ru) |
| SG (1) | SG11201903209TA (ru) |
| WO (1) | WO2018071736A1 (ru) |
| ZA (1) | ZA201902595B (ru) |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK66202C (da) | 1945-03-03 | 1948-01-12 | Danske Securitas As | Kodekontakt til elektriske Alarmanlæg. |
| DK71662C (da) | 1946-09-05 | 1950-11-06 | Ingenioer Frank Broadbent | Tørrecentrifuge. |
| US4049813A (en) | 1976-07-15 | 1977-09-20 | Sandoz, Inc. | Substituted isoxazolo pyridinones |
| US5837698A (en) * | 1996-05-02 | 1998-11-17 | G. D. Searle & Co. | Steroid nitrite and nitrate ester derivatives useful as anti-inflammatory drugs |
| CA2451057A1 (en) | 2001-06-14 | 2002-12-27 | Banyu Pharmaceutical Co., Ltd. | Novel isoxazolopyridone derivatives and use thereof |
| GB0119911D0 (en) | 2001-08-15 | 2001-10-10 | Novartis Ag | Organic Compounds |
| BRPI0416591A (pt) * | 2003-11-13 | 2007-01-30 | Combinatorx Inc | métodos e reagentes para o tratamento de distúrbios inflamatórios |
| CN101300265A (zh) * | 2005-09-02 | 2008-11-05 | 尼科克斯公司 | 糖皮质激素硝酰氧基衍生物 |
| CN1813768A (zh) * | 2005-11-18 | 2006-08-09 | 成都力思特制药股份有限公司 | 治疗呼吸系统疾病的药用组合物及其在制药中的应用 |
| KR20100087147A (ko) * | 2007-10-04 | 2010-08-03 | 아스트라제네카 아베 | 글루코코르티코이드 활성을 갖는 스테로이드성 [3,2-ｃ]피라졸 화합물 |
| US20110160167A1 (en) * | 2007-12-20 | 2011-06-30 | Astrazeneca Ab | Steroid Derivatives Acting As Glucocorticosteroid Receptor Agonists |
| US8173670B2 (en) | 2009-01-13 | 2012-05-08 | Van Andel Research Institute | Methods of using substituted isoxazolo pyridinones as dissociated glucocorticoids |
| UY32523A (es) | 2009-04-03 | 2010-10-29 | Astrazeneca Ab | Compuestos que tienen actividad agonista del receptor de glucocorticosteroides |
| UY32525A (es) * | 2009-04-03 | 2010-10-29 | Astrazeneca Ab | Compuestos que tienen actividad agonista del receptor de glucocorticosteroides |
| UY32520A (es) | 2009-04-03 | 2010-10-29 | Astrazeneca Ab | Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides |
| JP2012530140A (ja) | 2009-06-16 | 2012-11-29 | メルク・シャープ・アンド・ドーム・コーポレーション | グルココルチコイド受容体アゴニストとしての新規［３，２−ｃ］ヘテロアリールステロイド、組成物およびこの使用 |
| CN113845558A (zh) * | 2013-09-25 | 2021-12-28 | 范安德尔研究所 | 高效糖皮质激素 |
| TWI695831B (zh) * | 2014-09-13 | 2020-06-11 | 香港商南北兄弟藥業投資有限公司 | Ｃｒｔｈ２拮抗劑化合物及其用途 |
-
2017
- 2017-10-13 RU RU2019111101A patent/RU2019111101A/ru unknown
- 2017-10-13 EP EP17860202.5A patent/EP3525870B1/en active Active
- 2017-10-13 MA MA046539A patent/MA46539A/fr unknown
- 2017-10-13 SG SG11201903209TA patent/SG11201903209TA/en unknown
- 2017-10-13 WO PCT/US2017/056447 patent/WO2018071736A1/en unknown
- 2017-10-13 ES ES17860202T patent/ES2945983T3/es active Active
- 2017-10-13 KR KR1020197013291A patent/KR102497070B1/ko active IP Right Grant
- 2017-10-13 CN CN201780076320.7A patent/CN110382033B/zh active Active
- 2017-10-13 JP JP2019520039A patent/JP7146750B2/ja active Active
- 2017-10-13 US US16/341,275 patent/US10954265B2/en active Active
-
2019
- 2019-04-12 PH PH12019500801A patent/PH12019500801A1/en unknown
- 2019-04-24 ZA ZA2019/02595A patent/ZA201902595B/en unknown
-
2022
- 2022-07-14 JP JP2022113322A patent/JP2022132464A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| ES2945983T3 (es) | 2023-07-11 |
| RU2019111101A (ru) | 2020-11-16 |
| MA46539A (fr) | 2019-08-21 |
| EP3525870A4 (en) | 2020-04-29 |
| JP2022132464A (ja) | 2022-09-08 |
| JP7146750B2 (ja) | 2022-10-04 |
| KR102497070B1 (ko) | 2023-02-06 |
| ZA201902595B (en) | 2021-04-28 |
| WO2018071736A9 (en) | 2019-05-23 |
| EP3525870A1 (en) | 2019-08-21 |
| RU2019111101A3 (ru) | 2020-11-27 |
| EP3525870B1 (en) | 2023-05-10 |
| US10954265B2 (en) | 2021-03-23 |
| WO2018071736A1 (en) | 2018-04-19 |
| KR20190068577A (ko) | 2019-06-18 |
| CN110382033B (zh) | 2022-04-15 |
| US20190263853A1 (en) | 2019-08-29 |
| JP2019532071A (ja) | 2019-11-07 |
| CN110382033A (zh) | 2019-10-25 |
| PH12019500801A1 (en) | 2019-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201906883SA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201408261UA (en) | Syringe | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
| SG11201407837WA (en) | Beta-hairpin peptidomimetics | |
| SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201408617PA (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators |